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Abstract: Due to the increased interest in their application in the treatment of infectious diseases,
boron-containing compounds have received a significant coverage in the literature. Herein,
a small set of novel cinnamoly-oxaborole amides were synthesized and screened against nagana
Trypanosoma brucei brucei for antitrypanosomal activity. Compound 5g emerged as a new hit with
an in vitro IC50 value of 0.086 µM against T. b. brucei without obvious inhibitory activity against
HeLa cell lines. The same series was also screened against other human pathogens, including
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), for which moderate to weak
activity (10 to >125 µM) was observed. Similarly, these compounds exhibited moderate activity
against the human protozoal pathogen Trichomonas vaginalis with no observed effect on common
microbiome bacterial species. The cross-species inhibitory activity presents the possibility of these
compounds serving as broad-spectrum antibiotics for these prevalent three human pathogens.
Keywords: benzoxaboroles; cinnamic acids; trichomoniasis; trypanosomiasis; Mycobacterium
tuberculosis
1. Introduction
Globally, the major tropical infections malaria, tuberculosis (TB), trypanosomiasis,
and leishmaniasis remain a serious public health concern. Collectively, these infectious diseases
are responsible for more than 2.2 million deaths in developing countries annually [1]. Despite it being
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a preventable infectious disease, in 2015, approximately 1.8 million people died from TB infection [2].
A complete eradication of TB remains an incomplete task since drugs to treat these diseases are facing
several limitations including reduced efficacy, poor safety, and affordability [3]. A further complication
is the emergence of multidrug resistant Mycobacterium tuberculosis against clinically proven drugs,
which has made the development of new therapies a demanding task for effective management and
control of TB. Additionally, TB is considered a primary killer in HIV-positive individuals, and the World
Health Organization (WHO) reported that people living with HIV are at higher risk of developing TB
compared to healthy individuals [2]. In recent years, there have been reports of an overlap of endemic
regions between TB and parasitic diseases, which may result in co-infections of these diseases in the
affected population [4].
Human African trypanosomiasis (HAT), commonly referred to as a sleeping sickness [5], is a fatal
and debilitating disease which is included in the list of 17 neglected tropical diseases (NTDs) prioritized
by WHO [6–8]. Approximately 70 million people mainly residing in the remote areas of sub-Saharan
Africa are at risk of contracting the disease [9,10]. Human African trypanosomiasis is caused by
Trypanosoma brucei sub-species, namely T. b. rhodesiense and T. b. gambiense [11,12]. It is spread from
one person to another via the bite of an infected tsetse fly [13]. Although the causal agents of HAT
have been known for over a century, only four drugs, pentamidine, melarsoprol (Figure 1), suramin,
and eflornithine, are registered for the treatment of this disease [14]. These long-discovered drugs
have very poor oral bioavailability; as such, they are only administered intravenously, which is
expensive [15] and requires expertise and facilities that are inaccessible in disease stricken rural
areas [16], hampering treatment implementation [17]. In addition, these drugs also have serious side
effects [18] including nephrotoxicity, hypertension, anemia, and neuropathy [19]. Moreover, there are
growing concerns over the development of the drug-resistant infections against these drugs [20].
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Figure 1. Chemical structures of drugs for treatment of sleeping sickness and trichomoniasis. 
Similarly, individuals affected by parasitic diseases and bacterial infections are also exposed to 
sexually transmitted diseases [3]. Each year >340 million new cases of sexually transmitted bacterial 
and protozoal infections (STIs) occur globally [21,22]. Included in the list of STIs is human 
trichomoniasis, a non-viral disease that is caused by Trichomonas vaginalis. Contrary to infections 
such as chlamydia, gonorrhea, and syphilis, trichomoniasis receives less attention in terms of control 
efforts despite it being the most common disease of all [23]. Problems associated with trichomoniasis 
include premature rupture of membranes during pregnancy, premature birth, low birth weight, and 
enhancing the acquisition of HIV [24], an infectious virus posing a major threat especially in Africa. 
Nitroimidazoles, metronidazole, and tinidazole (Figure 1), are preferred drugs for treatment of T. 
vaginalis infections [25]. With the emerging resistance of T. vaginalis against metronidazole, there is 
no well-established alternative therapy available. 
Considering their attractive therapeutic and biological profile, in recent years, boron-containing 
compounds have received significant attention and are featuring prominently in literature [5,26–33]. 
Typical examples of these compounds are benzoxaboroles, which are cyclic boronic acids with 
robust stability under elevated acidic and basic conditions. Initially discovered by Torssell in 1957 
[34], benzoxaboroles have been hailed as potent anti-infective agents [26–29] that are non-toxic and 
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Similarly, individuals affected by parasitic diseases and bacterial infections are also exposed
to sexually transmitted diseases [3]. Each year >340 million new cases of sexually transmitted
bacterial and protozoal infections (STIs) occur globally [21,22]. Included in the list of STIs is human
trichomoniasis, a non-viral disease that is caused by Trichomonas vaginalis. Contrary to infections
such as chlamydia, gonorrhea, and syphilis, trichomoniasis receives less attention in terms of control
efforts despite it being the most common disease of all [23]. Problems associated with trichomoniasis
include premature rupture of membranes during pregnancy, premature birth, low birth weight,
and enhancing the acquisition of HIV [24], an infectious virus posing a major threat especially in
Africa. Nitroimidazoles, metronidazole, and tinidazole (Figure 1), are preferred drugs for treatment of
T. vaginalis infections [25]. With the emerging resistance of T. vaginalis against metronidazole, there is
no well-established alternative therapy available.
Considering their attractive therapeutic and biological profile, in recent years, boron-containing
compounds have received significant attention and are featuring prominently in literature [5,26–33].
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Typical examples of these compounds are benzoxaboroles, which are cyclic boronic acids with robust
stability under elevated acidic and basic conditions. Initially discovered by Torssell in 1957 [34],
benzoxaboroles have been hailed as potent anti-infective agents [26–29] that are non-toxic and
possess desirable chemical properties as well as pharmacokinetic properties [31]. Recent endeavors
aimed at discovering novel trypanocidal agents have culminated in new chemical entities (NCEs)
entering clinical trials [35], one of which is SCYX-7158 (1)—a benzoxaborole-based compound [36]
(Figure 2). Due to high attrition rates during clinical development of NCEs [37], it is imperative
to replete the trypanocidal drug development pipeline with numerous and structurally diverse
benzoxaborole-based leads. Typical examples of other promising novel benzoxaborole-containing
compounds include compound 2 (Figure 2), which showed excellent trypanocidal activity with in vitro
IC50 value of 0.14 µg/mL against T. b. brucei S427 [38]. Furthermore, compounds 3a and 3b (Figure 2)
are two examples of cinnamic acid-based benzoxaborole derivatives, which have been studied as
antifungal agents [39].
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2,5-bisacylaminobenzonephone (Figure 2, Compound 4) obtained by replacing a 
3-phenylpropanamide unit with 3-phenylprop-2-enamide unit. This prompted us to explore the 
biological activity of compounds containing the-prop-2-enamide unit coupled with 
6-aminobenzoxaborole, which is an appealing scaffold with antiprotozoal properties. Except the 
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More importantly, cinnamic acids are a class of compounds, which have received considerable
attention as promising anti-infective agents [40]. Several studies have shown that cinnamic acid
and their corresponding phenolic derivatives exhibit a broad spectrum of biological activities
including antiproliferative, antioxidant, antiviral, antimicrobial, antimalarial, and anti-cardiovascular
activities [40–42]. For example, Wiesner and co-workers [43] reported the antimalarial activity of
2,5-bisacylaminobenzonephone (Figure 2, Compound 4) obtained by replacing a 3-phenylpropanamide
unit with 3-phenylprop-2-enamide unit. This prompted us to explore the biological activity of
compounds containing the-prop-2-enamide unit coupled with 6-aminobenzoxaborole, which is
an appealing scaffold with antiprotozoal properties. Except the cinnamic acid-based benzoxaborole
derivatives (Figure 2, Compounds 3a and 3b), there is no previous literature report on this class of
compounds as potential antiprotozoal agents. Hence, herein we wish to report on the synthesis and
in vitro biological evaluation of novel cinnamoyl-oxaborole amides (Figure 2, Compound 5).
2. Results and Discussion
2.1. Chemistry
The synthesis of all intermediates and target compounds is presented in Scheme 1 below.
Briefly, the commercially accessible benzoxaborole 6 was treated with nitric acid at −30 to −40 ◦C to
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form 6-nitrobenzoxaborole intermediate, and subsequently reduced to form 6-aminobenzoxaborole 7
under hydrogen atmosphere using palladium on carbon catalyst [44]. With the 6-aminobenzoxaborole
7 in hand, we turned our attention to the activation of cinnamic acids 8 for coupling with 7 to form the
desired target cinnamoly-oxaborole amides 5a–g. Initially, we tried in situ activation of the carboxylic
acid group of cinnamic acids for amidation using different coupling agents such as CDI, EDCI, HOBt,
HOSu [45], and upon addition of 6-aminobenzoxaborole 7 these coupling agents all gave traces of
desired products. We then opted for the conversion of cinnamic acids to their more reactive cinnamoyl
chloride derivatives [46]. The common method of converting carboxylic acids to acyl chlorides,
which makes use of SOCl2 [47] was attempted, and upon coupling with 6-aminobenzoxaborole 7,
the reaction gave poor yields, and in some cases the desired products could not be isolated.
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Sche e 1. Synthesis of cinnamoyl-benzoxaborole amides 5a–g. Reagents and conditions:
(i) 99% HNO3, −30 ◦C, 3 h; (ii) H2, Pd/C, r.t, 2 h; (iii) DCM, Et3N, POCl3 and then (iv) DMAP.
We then adopted an alternative method using POCl3 in the presence of Et3N, an organic base.
The presence of an organic base to maintain a basic environment has been reported to be important for
acylation reactions of this type [48]. Thus, cinnamic acids 8 were treated with phosphoryl chloride
under nitrogen atmosphere to form in situ the corresponding cinnamoyl chloride intermediates 9a–g.
6-Aminobenzoxaborole 7 was then acylated with the intermediates 9a–g to form targeted compounds
5a–g in 29 to 46% yields.
The synthesized cinnamoyl-oxaboroles (Scheme 1, 5a–g) were characterized using 1H and
13C nuclear magnetic resonance (NMR) as well as high resolution mass spectrometry (HRMS).
The 1H-NMR spectra of all compounds showed a signal at δ ca 10.27 ppm assigned to B-OH. The peak
at δ ca 9.24 ppm is assigned to -NH of the amide bond. Two doublets (J = 15.0 and 15.6 Hz) at δ
ca 6.87 and 7.60 ppm are attributed to the two -CH of prop-2-enamide. These coupling constants
are consistent with a trans geometry at the double bond. The signal at δ ca 4.96 ppm is assigned
to the oxaborole -CH2. The 13C-NMR spectra of all compounds confirmed the skeletal structures
consistent with proposed compounds 5a–g. The non-appearance of the carbon adjacent to the boron
atom was noted, which is a common trend in benzoxaborole-containing compounds [49]. Analysis
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of the HRMS revealed molecular ion peaks agreeing with overall molecular structures of achieved
compounds. The purity of all compounds was determined to be greater than 96% using qualitative
high performance liquid chromatography (HPLC) (reversed phase).
2.2. Pharmacology
All target compounds were screened for in vitro inhibitory activity against the 427 strain of
T. b. brucei, the T. vaginalis parasite, and M. tuberculosis H37Rv. The cytotoxicity of all compounds
was assessed against human cervix adenocarcinoma (HeLa) cell line and emetine was used as
a control. At a 20 µM concentration of each compound, none of the compounds showed any toxic
effects to the HeLa cell line, and >80% cell viability was maintained during a 48 h exposure to the
compounds (Table 1. At this concentration, all tested compounds exhibited greater than 90% growth
inhibition of trypanosome parasites. Based on the single concentration screening data, the IC50
values were determined for compound 5a–g; the results are summarized in Figure 3 and Table 2.
The cinnamoly-oxaborole amides showed promising antitrypanosomal activity with IC50 values in the
low micromolar to sub-micromolar range. Despite being slightly less active compared to compounds 1
and 2, compounds 5a–e showed good activity with IC50 values below 1 µM and compound 5g emerged
as the most active compound with IC50 value of 0.086 µM against the T. b. brucei parasite. Pentamidine
was used as a positive control antitrypanosomal drug (IC50 = 1.2 nM).
Table 1. In vitro antimycobacterial, antitrichomonas, and cytotoxicity activities of cinnamic
acid-benzoxaborole hybrids.
Compound IC50 (µM) MIC99 (µM) %Viability
T. vaginalis H37Rv HeLa Cells
5a 15.3 ± 0.33 61.8 108.5 ± 5.35
5b 41.7 ± 0.23 107 87.0 ± 1.59
5c 10.2 ± 0.56 26.5 94.3 ± 28.8
5d 12.6 ± 0.28 10.7 89.9 ± 5.12
5e 11.7 ± 0.28 18.7 102.5 ± 2.34
5f >50 >125 109.9 ± 0.84
5g 22.8 ± 1.02 40.7 131.5 ± 26.6
EM - - 3.195
ME 0.53 - -
RE - 0.003 -
EM = emetine, ME = metronidazole, RE = rifampicin.
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Table 2. In vitro antitrypanosomal activities of cinnamic acid-benzoxaborole hybrids.
Compound IC50 (µM)
1 0.292 ± 0.019 a
2 0.14 b
5a 0.13 ± 0.02
5b 0.13 ± 0.01
5c 0.92 ± 0.04
5d 0.47 ± 0.04
5e 0.66 ± 0.03
5f 8.71 ± 0.65
5g 0.086 ± 0.002
PE 0.0012 ± 0.0001
a IC50 in µg/mL from reference 33, b IC50 in µg/mL from reference 38, PE = pentamidine.
Consistent with other studies [43,50–54] our data seem to suggest that linking of the cinnamoyl
framework with bioactive scaffolds lead to compounds showing superior activity. The more active
compounds also displayed excellent selectivity for the trypanosomal parasites over the human
HeLa cell line. Thus far, the preliminary structure-activity relationship (SAR) suggested that
mono-substituted aryl moieties are preferred for activity. More importantly, bicyclic aryl frameworks
as observed for compound 5g emerged as promising ring systems, which are worth further exploration.
Interestingly, inhibitory activity profiles for both mycobacteria and trichomonad parasites revealed
similar SAR, suggesting that the cellular targets of these compounds may be similar, even though
mycobacteria are prokaryotic and trichomonads are eukaryotic pathogens. Also, given that
trichomonad parasites co-exist with a mucosal microbiome, screening of these compounds showed
no detectable effects on normal flora bacterial growth in vitro. Taken together, these compounds
may present a new scaffold for drug discovery against human trypanosomiasis, tuberculosis, and
human trichomoniasis.
Target compounds 5a–g were also evaluated for antimycobacterial activity in vitro. To this end,
the compounds were screened in a broth microdilution assay against Mycobacterium tuberculosis
H37Rv (Mtb) using rifampicin as a standard. The antimycobacterial activities are reported as
minimum inhibitory concentration (MIC99) required to inhibit mycobacterial growth by 99%.
Antimycobacterial activities are incorporated in Table 1. More than 50% of the compounds exhibited
antimycobacterial activities, although these were moderate with respect to activity of the standard,
rifampicin (MIC99 0.003 µM). Starting from compound 5a (MIC99 61.8 µM), di-substitution of the aryl
moiety resulted in the loss of activity (e.g., 5f, MIC99 > 50 µM), while mono-substitution enhances
activity (e.g., 5e, MIC99 18.7 µM). The para-substituted aryl analogues showed the best activities
(5d, MIC99 10.7 µM).
3. Materials and Methods
3.1. General Information
All chemicals and solvents used were purchased from Sigma-Aldrich (Pty) Ltd (Johannesburg,
South Africa) and Merck (Pty) Ltd (Johannesburg, South Africa) and were used without further
purification. Reactions were monitored by analytical thin layer chromatography (TLC) using Merck
F254 silica gel plates (Merck, Johannesburg, South Africa) supported on aluminum sheets and the plates
were visualized under ultraviolet (UV 254 and 366 nm) light and in iodine flasks. Where necessary,
the crude compounds were purified by a silica gel column chromatography using Merck Kieselgel
60 Å:70–230 (0.068–0.2 mm) silica gel mesh (Merck, Johannesburg, South Africa). The 1H and
13C-NMR spectra were recorded on Bruker Biospin 300, 400 or 600 MHz spectrometers, and were
referenced internally using residual solvent signals of deuterated DMSO-d6: 2.50 ppm for 1H and
39.5 ppm for 13C-NMR, or deuterated chloroform CDCl3: 7.26 ppm for 1H and 77.2 ppm for
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13C-NMR at ambient temperature. The high-resolution mass spectrometric data (HRS-MS) of the
final compounds was recorded on Waters Synapt G2 Mass Spectrometer (Stellenbosch University,
Stellenbosch, South Africa) using electron impact (EI) ionization in the positive ionization mode.
The starting 6-aminobenzoxaborole 7 was synthesized from the commercial 6-nirobenzoxaborole 6
(see Supplementary Materials) as previously described in the literature [31,55]. Purity was determined
by HPLC (Agilent, Santa Clara, CA, USA), and all compounds were confirmed to have a purity of >95%.
The chromatographic system consisted of an Agilent HP1100 LC-MSD (Agilent, Santa Clara, CA, USA)
and equipped with a quaternary pump, in-line degasser, DAD detector, 1100 MSD and ChemStation
for collection and analysis of data. A ZORBAX Elipse Plus C18 4.6 i.d. × 150 mm × 5 µm column was
used for reversed-phase HPLC analysis. A mobile phase consisting of a mixture of aqueous solution
of monobasic sodium phosphate 0.01 M and acetonitrile (90:10) on isocratic elution mode was used.
Five different concentrations (5–500 µg/mL) of samples to be analyzed were made, filtered using
0.45 µm Millipore filters before their injection.
3.2. General Synthetic Procedure for the Cinnamic Acid-Benzoxaborole Hybrids, 5a–g
A mixture of cinnamic acids 2 (0.5 mmol) and Et3N (1.2 mmol) in anhydrous CH2Cl2 (1.5 mL)
under N2 atmosphere was stirred at 0 ◦C for 5 min, then POCl3 (0.5 mmol) in anhydrous CH2Cl2
(1 mL) was added and the resulting mixture allowed to stir at room temperature for 30 min. When the
acids were completely consumed (TLC), a solution of DMAP (0.15 mmol) and 6-aminobenzo[c]
[1,2]oxaborol-1(3H)-ol (0.6 mmol) in anhydrous CH2Cl2 (0.5 mL) was added dropwise and the mixture
stirred overnight at room temperature. Upon completion, the reaction mixture was washed sequentially
with ice-cold water (10 mL), 10% aqueous HCl (10 mL), saturated aqueous NaHCO3 solution (10 mL),
brine, and dried over anhydrous MgSO4. The solvent was removed in vacuo to give a solid residue,
which was purified by flash column chromatography to afford the pure products, 5a–g.
(E)-N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)cinnamamide (5a). Off white solid.
Yield = 41%. m.p.: 182–184 ◦C. 1H-NMR (300 MHz, DMSO-d6) δH (ppm): 10.28 (1H, s, B-OH),
9.25 (1H, s, NH), 8.11 (1H, d, J = 1.8 Hz, Ar-H9), 7.78 (1H, dd, J = 1.8 and 6.3 Hz, Ar-H10), 7.65–7.56
(3H, m, Ar-H7/H6/H2), 7.46–7.34 (4H, m, Ar-H11, Ar-H5, Ar-H4, Ar-H3), 6.90 (1H, d, J = 15.6 Hz,
H8), 4.96 (2H, s, H12). 13C-NMR (75 MHz, DMSO-d6) δ (ppm): 163.6, 149.4, 140.4, 138.6, 135.3, 130.1,
129.6, 128.2, 122.9, 122.8, 122.1, 121.5, 70.2. m/z (ESI-MS) found 280.1146 [M + H]+, expected 279.1067.
HPLC purity = 99.3%, retention time = 1.01 min.
(E)-N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-3-(3-nitrophenyl)acrylamide (5b). Yellow
solid. Yield = 48%. m.p.: 176–178 ◦C. 1H-NMR (300 MHz, DMSO-d6) δH (ppm): 10.23 (1H, s, B-OH),
8.09 (1H, d, J = 3.0 Hz, Ar-H9), 8.77 (1H, dd, J = 3.0 and 6.0 Hz, Ar-H10), 7.52 (1H, d, J = 15.0 Hz,
H7), 7.35 (1H, d, J = 6.0 Hz, Ar-11), 7.20–7.13 (2H, m, H4, H2),7.03–6.96 (1H, m, Ar-H6), 6.90–6.82
(1H, m, Ar-H5), 6.73 (1H, d, J = 15.0 Hz, H8), 4.94 (2H, s, H12). 13C-NMR (75 MHz, DMSO-d6)
δC (ppm):164.5, 149.4, 148.7, 140.4, 138.9, 129.9, 124.1, 122.9, 122.4, 121.7, 121.1, 109.4, 107.0, 102.2, 70.4.
m/z (ESI-MS) found 324.1046 [M]+, expected 324.0918. HPLC purity = 92.5%, retention time = 1.43 min.
(E)-N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-3-(4-nitrophenyl)acrylamide (5c). Yellow solid.
Yield = 42%. m.p.: 176–180 ◦C.1H-NMR (600 MHz, DMSO-d6) δH (ppm): 10.42 (1H, s, B-OH),
9.29 (1H, s, H10), 8.29 (2H, d, J = 9.0 Hz, Ar-Hf), 8.10 (1H, d, J = 1.5 Hz, Ar-H7), 7.90 (2H, d, J = 9.0 Hz,
Ar-He), 7.77 (1H, dd, J = 1.8, 9.0 Hz, Ar-H5), 7.70 (1H, d, J = 15.6 Hz, Hb), 7.39 (1H, d, J = 8.4 Hz,
Ar-H4), 7.05 (1H, d, J = 15.0 Hz, Hc), 4.96 (2H, s, H3). 13C-NMR (151 MHz, DMSO-d6) δC (ppm): 163.3,
149.6, 148.1, 141.8, 138.4, 138.0, 129.2, 127.2, 124.6, 122.8, 122.2, 121.6. 70.3. ESI-HRMS m/z calcd. for
C16H13BN2O5 324.0918, found 325.1005 [M + H]+. HPLC purity = 99.1%, retention time = 1.33 min.
(E)-3-(4-Bromophenyl)-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)acrylamide (5d). Off white
solid. Yield = 29%. m.p.: 206–210 ◦C. 1H-NMR (300 MHz, DMSO-d6) δH (ppm):10.33 (1H, s, B-OH),
9.28 (1H, s, H10), 8.32 (1H, d, J = 2.8 Hz, Ar-H7), 8.06 (1H, dd, J = 3.0, 6.0 Hz, Ar-H5), 7.61–7.51 (4H, m,
Ar-He, -Hf), 7.53 (1H, d, J = 15.0 Hz, Hb), 7.36 (1H, d, J = 9.0 Hz, Ar-4), 6.87 (1H, d, J = 15.0 Hz, Hc),
4.94 (2H, s, H3). 13C-NMR (75 MHz, DMSO-d6) δC (ppm): 163.9, 149.6, 139.3, 139.3, 138.3, 134.4, 132.4,
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130.2, 123.4, 123.0, 122.2, 121.6, 70.2. ESI-HRMS m/z calcd. for C16H13BBrNO3 357.0172, found 358.0250
[M + H]+. HPLC purity = 98.4%, retention time = 0.67 min.
(E)-N-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-3-(4-methoxyphenyl)acrylamide (5e). Off white
solid. Yield = 32%. m.p.: 190–192 ◦C. 1H-NMR (300 MHz, DMSO-d6) δH (ppm): 10.19 (1H, s, B-OH),
9.25 (1H, s, NH), 8.09 (1H, d, J = 1.2 Hz, Ar-H9), 7.75 (1H, dd, J = 1.8 and 6.6 Hz, Ar-H10), 7.54 (1H, d,
J = 15.0 Hz, H7), 7.36 (1H, d, J = 9.0 Hz, Ar-11), 7.01 (2H, d, J = 9.0 Hz, Ar-H2, H6), 6.97 (2H, d, J = 9.0 Hz,
Ar-H5, H3), 6.74 (1H, d, J = 15.0, H8), 4.95 (2H, s, H12), 3.15 (3H, s, H4’). 13C-NMR (75 MHz, DMSO-d6)
δC (ppm): 168.4, 164.4, 161.1, 149.3, 138.9, 130.5, 130.57, 130.0, 127.8, 127.7, 120.6, 115.1, 70.5, 56.1. m/z
(ESI-MS) found 310.1252 [M + H]+, expected 309.1172. HPLC purity = 99.5%, retention time = 0.95 min.
(E)-3-(3,4-Dimethoxyphenyl)-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)acrylamide (5f).
Pale yellow solid. Yield = 46%. m.p.: 188–190 ◦C. 1H-NMR (300 MHz, DMSO-d6) δH (ppm):
10.20 (1H, s, B-OH), 9.35 (1H, s, NH), 8.05 (1H, d, J = 2.6 Hz, Ar-H9), 7.71 (1H, dd, J = 3.0 and 6.0 Hz,
Ar-H10), 7.51 (2H, d, J = 15.6 Hz, H7), 7.35 (1H, d, J = 9.0 Hz, Ar-11), 7.20–7.13 (2H, m, H5, H2),
6.98 (1H, d, J = 9.0 Hz, H6), 6.73 (1H, d, J = 15.0, H8), 4.93 (2H, s, H12), 3.79 (6H, s, H4’, H3). 13C-NMR
(75 MHz, DMSO-d6) δC (ppm): 168.9, 164.9, 151.2, 151.6, 149.7, 141.2, 138.8, 128.1, 127.7, 123.4, 122.7,
122.5, 122.0, 120.6, 110.9, 56.4, 56.3. m/z (ESI-MS) found 340.1357 [M + H]+, expected 339.1278. HPLC
purity = 97.1%, retention time = 1.28 min.
(E)-3-(Benzo[d][1,3]-6-dioxol-5-yl)-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)acrylamide (5g).
Pale yellow solid. Yield = 38%. m.p.: 145–148 ◦C. 1H-NMR (400 MHz, DMSO-d6) δH (ppm): 10.64
(1H, s, B-OH), 9.30 (1H, s, NH), 8.47 (2H, s, Ar-H7), 8.24 (1H, d, J = 8.0 Hz, Ar-H7), 8.14 (1H, s, Ar-He),
7.81 (1H, d, J = 6.3 Hz, Ar-4), 7.76 (1H, d, J = 7.6 Hz, Ar-i), 7.71 (1H, d, J = 16.0 Hz, Hb), 7.37 (1H, d,
J = 8.0 Hz, Ar-Hh), 7.20 (1H, d, J = 16.0 Hz, Hc), 4.98 (2H, s, H3), 1.98 (2H, s, Hk). 13C-NMR (75 MHz,
DMSO-d6) δC (ppm):170.7, 163.0, 149.4, 148.8, 138.4, 137.8, 134.4, 130.8, 125.9, 124.2, 122.1, 121.5, 70.1,
60.1. ESI-HRMS m/z calcd for C17H14BNO5 323.0965, found 325.0995 [M + H]+. HPLC psurity = 100%,
retention time = 1.40 min.
3.3. In Vitro Antitrypanosomal Assay
Trypanosoma brucei brucei 427 trypomastigotes were cultured in Iscove’sss Modified Dulbecco’s
medium (IMDM, Lonza, Basel Switzerland) supplemented with 10% fetal calf serum, HMI-9
supplement [56], hypoxanthine, and penicillin/streptomycin at 37 ◦C in a 5% CO2 incubator.
Serial dilutions of test compounds were incubated with the parasites in 96-well plates for 24 h and
residual parasite viability in the wells determined by adding 20 µL resazurin toxicology reagent
(Sigma-Aldrich) and incubating for an additional 2–4 h. Reduction of resazurin to resorufin by viable
parasites was assessed by fluorescence readings (excitation 560 nm, emission 590 nm) in a Spectramax
M3 plate reader (Molecular Devices, San Jose, CA, USA). Fluorescence readings were converted to %
parasite viability relative to the average readings obtained from untreated control wells. IC50 values
were determined by plotting % viability vs. log[compound] and performing non-linear regression
using GraphPad Prism (v. 5.02) software [57].
3.4. In Vitro Cytotoxicity Assay
HeLa cells (Cellonex, Johannesburg, South Africa) seeded in 96-well plates were incubated with
20 µM test compounds for 24 h and cell viability assessed using a resazurin fluorescence assay as
previously described [57].
3.5. In Vitro Antitrichomonal Assay and Mucosal Normal Flora Susceptibility Assay
Axenic cultures of the Trichomonas vaginalis G3 strain (the genome strain) were grown in 5 mL
TYM Diamond’s medium (containing equine serum and antibiotics) in a 37 ◦C incubator for 24 h.
One hundred millimolar stocks of the compounds were made by dissolving in DMSO and were
screened against G3 stain of T. vaginalis. Cells that are untreated and treated with 5 µL DMSO
(0.1% final concentration) were used as controls. Five milliliters of the 100 mM stocks of the compound
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library were added for a final concentration of 50 mM. Results were calculated based on manual counts
utilizing a hemocytometer after 24 h (parasite motility being the criteria for viability). The IC50 values
were determined by titration of the stock solutions and hemocytometer counting as described above.
Data were plotted on GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA) and theoretical
IC50 values were determined. To confirm the IC50 values, the predicted values were then re-tested
as described above. Non-pathogenic mucosal normal flora strains such as Lactobacillus reuteri (ATCC
23272, Lactobacillus acidophilus (ATCC 43560), and Lactobacillus rhamnosus (ATCC 53103) were cultured in
Lactobacilli MRS at 37 ◦C under anaerobic conditions. One hundred milliMolar stock solutions as well
as vehicle control DMSO were diluted to 100 µM in media and incubated with empty BDL-sensi-discs
(6 mm) for 20 min at room temperature. Discs containing vehicle control, compounds, or various
antibiotic discs [levofloxacin (5 µg), gentamicin (10 µg), and gentamicin (120 µg)] were placed onto
the bacterial streaked agar plates and incubated overnight at 37 ◦C. Vehicle, compound, or antibiotic
sensitivity was determined via measurement of zones of inhibition around each disc in mm.
3.6. In Vitro Antimycobacterial Assay
The minimum inhibitory concentration (MIC) was determined using the standard broth micro
dilution method, where a 10 mL culture of Mycobacterium tuberculosis pMSp12:GFP [58], was grown
to an optical density (OD600) of 0.6–0.7. The media used were: (i) Gaste-Fe (glycerol-alanine-salts)
medium pH 6.6, supplemented with 0.05% Tween-80 and 1% Glycerol, and (ii) 7H9 supplemented
with 10% Albumin Dextrose Catalase supplement (ADC), 0.05% Tween-80 [59,60]. Cultures grown in
Gaste-Fe were diluted 1:100, and cultures grown in 7H9 ADC were diluted 1:500, prior to inoculation
of the MIC assay. The compounds to be tested are reconstituted to a concentration of 10 mM in
DMSO. Two-fold serial dilutions of the test compound are prepared across a 96-well micro titre plate,
after which, 50 µL of the diluted M. tuberculosis cultures were added to each well in the serial dilution.
The plate layout was a modification of the method previously described [61]. Assay controls used were
a minimum growth control (Rifampicin at 2 × MIC), and a maximum growth control (5% DMSO).
The micro titre plates were sealed in a secondary container and incubated at 37 ◦C with 5% CO2
and humidification. Relative fluorescence (excitation 485 nM; emission 520 nM) was measured using
a plate reader (FLUOstar OPTIMA, BMG LABTECH, Ortenberg, Germany), at day 7 and day 14.
The raw fluorescence data were archived and analyzed using the CDD Vault from Collaborative Drug
Discovery, in which, data were normalized to the minimum and maximum inhibition controls to
generate a dose response curve (% inhibition), using the Levenberg-Marquardt (Burlingame, CA, USA
www.collaborativedrug.com) damped least squares method, from which the MIC90 was calculated.
The lowest concentration of drug that inhibits growth of more than 90% of the bacterial population
was considered the MIC90.
4. Conclusions
In summary, the current drugs used to treat sleeping sickness have serious side effects, and in most
cases, showed poor efficacy. Therefore, there is a need to search for new and better treatment options.
Benzoxaborole-containing lead compounds have demonstrated promising efficacy and desirable
drug-like properties. Due to high attrition in clinical development, it is essential to replete the drug
development pipeline with structurally diverse leads. In this study, a small set of cinnamoyl-oxaborole
molecules was synthesized and evaluated for trypanocidal activity; and for activity against other
prevalent human pathogens. Compound 5g emerged as new hit with improved activity compared to
compound 2 against T. b. brucei. Against other pathogens evaluated in this study, these compounds
displayed moderate to weak activity without any obvious cytotoxic effect.
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